Wang Luyang, Shao Qipeng, Wu Haiyang, Li Cheng
Department of Orthopaedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Orthopaedics, Ganzhou People's Hospital, Ganzhou, China.
Front Endocrinol (Lausanne). 2025 Jul 7;16:1618984. doi: 10.3389/fendo.2025.1618984. eCollection 2025.
Diabetes mellitus is strongly associated with accelerated intervertebral disc degeneration, a condition that significantly contributes to lower back pain and reduced quality of life. Emerging evidence indicates that advanced glycation end products (AGEs) are key mediators in the pathophysiology of disc degeneration through the stimulation of inflammatory pathways, promotion of oxidative stress, and induction of extracellular matrix modifications. This review critically examines current literature on the role of AGEs in diabetic disc degeneration and evaluates potential therapeutic interventions aimed at mitigating these deleterious effects. Targeting AGEs represents a promising therapeutic avenue to mitigate diabetic intervertebral disc degeneration. The current evidence supports the rationale for further investigation into AGE inhibitors, cross-link breakers, and receptor for AGEs modulators as potential treatment strategies. However, to translate these findings into clinical practice, well-designed clinical trials are required to validate the efficacy and safety of these interventions, as well as to optimize treatment protocols.
糖尿病与椎间盘退变加速密切相关，这种情况会显著导致下背部疼痛并降低生活质量。新出现的证据表明，晚期糖基化终末产物（AGEs）是椎间盘退变病理生理学中的关键介质，通过刺激炎症途径、促进氧化应激和诱导细胞外基质修饰来发挥作用。本综述批判性地审视了当前关于AGEs在糖尿病性椎间盘退变中作用的文献，并评估了旨在减轻这些有害影响的潜在治疗干预措施。针对AGEs是减轻糖尿病性椎间盘退变的一条有前景的治疗途径。目前的证据支持将AGE抑制剂、交联断裂剂和AGE受体调节剂作为潜在治疗策略进行进一步研究的理论依据。然而，要将这些研究结果转化为临床实践，需要精心设计的临床试验来验证这些干预措施的有效性和安全性，并优化治疗方案。
